艾伯维公司(ABBV)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ABBV 艾伯维公司

休市中 09-25 16:00:00 EDT

264.34

-0.78

-0.29%

盘后265.00

+0.66+0.25%

19:59 EDT

最高266.00	最低262.59	成交量254.17万
今开265.49	昨收265.12	日振幅1.29%
总市值4,672亿	流通市值4,660亿	总股本17.67亿
成交额6.72亿	换手率0.14%	流通股本17.63亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ABBV","market":"US","secType":"STK","nameCN":"艾伯维公司","latestPrice":264.34,"timestamp":1790366400000,"preClose":265.12,"halted":0,"volume":2541718,"hourTrading":{"tag":"盘后","latestPrice":265,"preClose":264.34,"latestTime":"19:59 EDT","volume":350100,"amount":92545521.9987,"timestamp":1790380771745,"change":0.66,"changeRate":0.002497,"amplitude":0.002497},"delay":0,"changeRate":-0.002942063971032097,"floatShares":1762950764,"shares":1767384632,"eps":3.539701,"marketStatus":"休市中","change":-0.78,"latestTime":"09-25 16:00:00 EDT","open":265.49,"high":266,"low":262.59,"amount":671528681.9870601,"amplitude":0.012862,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":3.539701,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1790582400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":265.12,"dividendRate":0.025838,"preHourTrading":{"tag":"盘前","latestPrice":266,"preClose":265.12,"latestTime":"09:28 EDT","volume":1195,"amount":316268.1025,"timestamp":1790342897737,"change":0.88,"changeRate":0.003319,"amplitude":0.018505},"postHourTrading":{"tag":"盘后","latestPrice":265,"preClose":264.34,"latestTime":"19:59 EDT","volume":350100,"amount":92545521.9987,"timestamp":1790380771745,"change":0.66,"changeRate":0.002497,"amplitude":0.002497},"volumeRatio":0.5964107855736855,"impliedVol":0.29,"impliedVolPercentile":0.5538},"requestUrl":"/m/hq/s/ABBV","defaultTab":"news","newsList":[{"id":"2669117143","title":"艾伯维（ABBV）Rinvoq获欧盟批准 已拥有11项免疫炎症疾病获批适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2669117143","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669117143?lang=zh_cn&edition=full","pubTime":"2026-09-22 16:44","pubTimestamp":1790066647,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据外媒报道，艾伯维（ABBV）周二宣布，Rinvoq获欧盟批准，用于治疗对一种或多种改善病情抗风湿药（DMARD）应答不足或不耐受的2岁及以上活动性多关节型幼年特发性关节炎患者。艾伯维表示，Rinvoq可单药使用，也可与甲氨蝶呤联合用药。本次获批依据开放标签Ⅰ期SELECT-YOUTH研究以及成人类风湿关节炎的相关临床数据，同时该药物全新口服溶液剂型也获批用于pJIA患者。此外，Rinvoq在欧盟已获批11项针对各类免疫介导性炎症性疾病的适应症。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/YjU2YzAxODc0YzFlOTM1Nzk3MTU1NDIzZDRjODY4MTE1MzM5MTg2.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/YjU2YzAxODc0YzFlOTM1Nzk3MTU1NDIzZDRjODY4MTE1MzM5MTg2.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"306308","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABBV","LU0128525929.USD","LU0122379950.USD","LU2023251221.USD","FHLC","LU0823416689.USD","LU1551013425.SGD","XLV","SG9999015978.USD","LU0029864427.USD","MEDX","FESXmain","LU0868494708.USD","LU1162221912.USD","FSXEmain","IE00BN8TJ469.HKD","IYH","VHT","AGNG","LU0985320562.USD","LU0545039389.USD","JDOC","RXL","IE00BJJMRZ35.SGD","BK4559","IE00BBT3K403.USD","TRUH","LU0820561818.USD","BK4585","IE0002141913.USD","LU1061106388.HKD","LU0708994859.HKD","GLAM","IE0009355771.USD","LU0203345920.USD","LU2237443622.USD","IXJ","IE000SO60NU8.SGD","LU1923622614.USD","IE00BVYPNW00.USD","PPH","IE00B19Z3B42.SGD","IE0004445239.USD","LU0395794307.EUR","FTXH","LU1989772840.SGD","LU0661504455.SGD","LU0942090050.USD","PJP","LU1718418525.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143024609","title":"艾伯维宣布欧洲委员会批准Rinvoq®（乌帕替尼）用于治疗活动性多关节型幼年特发性关节炎儿童患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1143024609","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143024609?lang=zh_cn&edition=full","pubTime":"2026-09-22 14:01","pubTimestamp":1790056882,"startTime":"0","endTime":"0","summary":"艾伯维公司（AbbVie）今日正式宣布，欧洲委员会已批准其重磅药物Rinvoq®（通用名：乌帕替尼，Upadacitinib）扩大适应症范围，用于治疗患有活动性多关节型幼年特发性关节炎的儿童患者。这一决定标志着该药物在儿科风湿病学领域的又一重大突破。多关节型幼年特发性关节炎是一种罕见但严重的慢性自身免疫性疾病，主要影响儿童，可导致关节疼痛、肿胀乃至永久性关节损伤，长期以来一直缺乏充足且有效的治疗选择。此次获批，无疑为这些低龄患者及其家庭带来了新的希望与曙光。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1162221912.USD","LU0868494617.USD","ABBV","LU0795875169.SGD","LU0861579265.USD","GLAM","LU0320765646.SGD","LU0868494708.USD","FTXH","LU0203347892.USD","LU2237443382.USD","SG9999015952.SGD","LU1244550577.SGD","IE00B4R5TH58.HKD","LU2125909247.SGD","LU0170899867.USD","LU0289739699.SGD","SG9999003800.SGD","LU0114720955.EUR","IE0002141913.USD","LU0098860793.USD","LU0965509010.AUD","IE00BDGV0183.EUR","LU0158827948.USD","IE00BJT1NW94.SGD","LU1718418525.SGD","TRUH","LU2125909593.SGD","PJP","LU1720051017.SGD","LU0965508806.USD","LU0823416689.USD","LU1551013425.SGD","LU0395794307.EUR","MEDX","SG9999015945.SGD","LU2129689431.USD","LU0058720904.USD","SG9999015986.USD","LU0310800379.SGD","LU2347655156.SGD","LU2112291526.USD","IE000BZT7R73.USD","LU0795875086.SGD","LU1934455863.HKD","LU1093756325.SGD","LU1267930573.SGD","XLV","IE0004445239.USD","IE00B42XCP33.USD","LU2237443465.HKD","IXJ","IE00B2B36J28.USD","LU0708994859.HKD","LU0726765562.USD","VHT","LU1023059063.AUD","LU1037948897.HKD","LU1291159041.SGD","LU1037948541.HKD","LU0203345920.USD","LU0859254822.USD","IE00B19Z3B42.SGD","IE00BGHQF631.EUR","LU0965509283.SGD","IE000MB6IJN5.SGD","BK4585","IE00BVYPNV92.GBP","LU2089283258.USD","LU1548497426.USD","BK4559","IE00BN8TJ469.HKD","LU2433249047.HKD","LU0689626769.HKD","IE00BVYPNW00.USD","IE0002270589.USD","LU0472753341.HKD","LU0234572021.USD","LU1430594728.SGD","LU0820561909.HKD","LU0942090050.USD","LU1923622614.USD","LU0511384066.AUD","LU0965509101.SGD","LU1093756168.USD","IE00B3PB1722.GBP","LU0128525929.USD","IE00BBT3K403.USD","LU0912757837.SGD","LU1934455194.USD","IE000SO60NU8.SGD","LU0057025933.USD","LU0310799852.SGD","LU0949170772.SGD","IE0009355771.USD","PPH","LU0289961442.SGD","BK4139","LU0124676726.USD","SG9999011175.SGD","LU0234570918.USD","LU2023251221.USD","LU1839511570.USD","IE00BSNM7G36.USD","LU1989772840.SGD","FHLC","LU1989771016.USD","LU2237443549.SGD","IE00BJJMRZ35.SGD","IE0000B7K699.USD","LU0417517546.SGD","LU1003077747.HKD","LU2468319806.SGD","LU0882574055.USD","LU1057294990.SGD","LU1061106388.HKD","LU0661504455.SGD","LU0211327993.USD","IE00BLSP4239.USD","LU2089984988.USD","LU2347655073.USD","LU1732800096.USD","LU2237443978.SGD","LU0820561818.USD","LU1934455277.USD","LU0738911758.USD","BK4550","BK4534","LU1267930490.SGD","LU1236620750.USD","IE00B19Z3581.USD","LU2237443895.HKD","AGNG","JDOC","LU1585245621.USD","LU2129689514.USD","BK4581","SG9999015978.USD","RXL","BK4588","LU0211328371.USD","BK4533","LU2087621335.USD","LU0985320562.USD","LU1496350502.SGD","LU2357305700.SGD","LU2133065610.SGD","LU1720051108.HKD","LU0943347566.SGD","LU0553294199.USD","LU0432979614.USD","IYH","LU0122379950.USD","LU1496350171.SGD","LU0456855351.SGD","IE00BLSP4452.SGD","LU0029864427.USD","LU0256863811.USD","LU1989772923.USD","LU2089284900.SGD","LU1074936037.SGD","LU0256863902.USD","LU1929549753.HKD","LU2357627491.SGD","LU0289739343.SGD","LU0689472784.USD","IE000WAW04H5.SGD","LU0545039389.USD","LU1244550221.USD","LU1551013342.USD","LU2237443622.USD","LU1670628061.USD","SG9999001440.SGD","BK4566","IE00BFTCPJ56.SGD","LU1244550494.USD","LU2129689605.HKD","LU1670627923.USD","LU1236620834.HKD","LU1732799900.SGD","IE000F7OJYX1.SGD","LU0069063385.USD","LU1983299246.USD","LU0198837287.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669628161","title":"RNA疗法公司Adarx Pharmaceuticals(ADRX.US)拟赴美IPO募资至多3.72亿美元 制药巨头艾伯维(ABBV.US)已同意投资最高1亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669628161","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669628161?lang=zh_cn&edition=full","pubTime":"2026-09-21 23:58","pubTimestamp":1790006296,"startTime":"0","endTime":"0","summary":"处于临床后期开发阶段的RNA疗法公司Adarx Pharmaceuticals计划通过美国首次公开募股(IPO)筹集至多3.719亿美元资金","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260922/20260922000340_53804.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260922/20260922000340_53804.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1499033.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0211328371.USD","LU0395794307.EUR","IE000WAW04H5.SGD","ABBV","LU0726765562.USD","JDOC","IXJ","LU1236620834.HKD","RXL","LU1244550494.USD","PJP","LU0795875169.SGD","BK1574","IE0002141913.USD","LU1732799900.SGD","VHT","XLV","BK4581","IPOS","FTXH","GLAM","LU0820561909.HKD","BK4550","LU0965509101.SGD","LU2023251221.USD","MEDX","01477","AGNG","IE0009355771.USD","FHLC","TRUH","LU0965508806.USD","BK4585","LU0170899867.USD","LU1732800096.USD","IE00BDGV0183.EUR","KCE","BK4534","LU1093756168.USD","REDS","LU2089984988.USD","LU0289961442.SGD","IYH","LU1003077747.HKD","LU0256863902.USD","PPH","IE00B19Z3581.USD","LU1670628061.USD","FRHC","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109790453","title":"艾伯维达成合作，加速免疫学、神经科学与肿瘤学领域小分子药物研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1109790453","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109790453?lang=zh_cn&edition=full","pubTime":"2026-09-21 20:02","pubTimestamp":1789992130,"startTime":"0","endTime":"0","summary":"艾伯维公司宣布建立一项全新合作伙伴关系，旨在推动免疫学、神经科学以及肿瘤学领域的小分子药物发现进程。这一战略举措，标志着该公司在上述关键治疗领域的研发步伐将显著提速。通过整合外部创新资源与内部研发优势，艾伯维力求缩短药物从实验室走向临床的周期。此举不仅有望丰富其管线储备，也可能为疑难病症的治疗带来突破性方案。在当前医药行业竞争日趋激烈的背景下，此类协同合作愈发凸显其战略价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","BK4559","SG9999011175.SGD","LU0985320562.USD","LU0058720904.USD","LU0472753341.HKD","LU0289739699.SGD","IYH","IE0002270589.USD","IE00BJJMRZ35.SGD","IE00BVYPNW00.USD","LU2237443465.HKD","LU2129689514.USD","LU0417517546.SGD","LU0395794307.EUR","LU1267930573.SGD","FHLC","IE000BZT7R73.USD","LU1244550494.USD","IE0009355771.USD","LU1934455863.HKD","LU0289961442.SGD","LU1236620750.USD","LU2468319806.SGD","LU1162221912.USD","BK4550","LU0708994859.HKD","LU1670628061.USD","GLAM","IE00B2B36J28.USD","LU1989771016.USD","IE00BGHQF631.EUR","SG9999015945.SGD","SG9999015952.SGD","LU0114720955.EUR","LU1989772923.USD","LU2125909593.SGD","LU0158827948.USD","LU0211327993.USD","LU0198837287.USD","LU0823416689.USD","IE00BJT1NW94.SGD","LU2023251221.USD","LU2087621335.USD","IE00BBT3K403.USD","IE000SO60NU8.SGD","LU1923622614.USD","LU0689472784.USD","ABBV","LU0795875086.SGD","PPH","TRUH","JDOC","LU0795875169.SGD","LU1074936037.SGD","SG9999015986.USD","LU2357627491.SGD","LU0912757837.SGD","LU1670627923.USD","LU1057294990.SGD","LU0965509010.AUD","LU0553294199.USD","LU1093756325.SGD","IE00BFTCPJ56.SGD","LU2089984988.USD","LU1585245621.USD","LU0234572021.USD","LU0738911758.USD","LU1496350502.SGD","PJP","FTXH","LU1551013425.SGD","LU0128525929.USD","LU0211328371.USD","LU1244550577.SGD","IE000MB6IJN5.SGD","LU1934455277.USD","BK4588","LU1989772840.SGD","IE00BSNM7G36.USD","LU0859254822.USD","SG9999015978.USD","LU1430594728.SGD","LU2112291526.USD","LU2133065610.SGD","MEDX","LU0456855351.SGD","LU0661504455.SGD","LU1983299246.USD","BK4139","IE0004445239.USD","LU0965509101.SGD","LU0689626769.HKD","BK4534","LU1037948541.HKD","LU1023059063.AUD","LU2237443978.SGD","LU0820561818.USD","LU1236620834.HKD","LU0861579265.USD","LU0965509283.SGD","LU0949170772.SGD","IE0000B7K699.USD","LU0029864427.USD","LU0256863902.USD","IE00B42XCP33.USD","IXJ","LU1061106388.HKD","LU1934455194.USD","LU0511384066.AUD","LU1732799900.SGD","LU0965508806.USD","LU2129689605.HKD","RXL","LU2347655156.SGD","XLV","IE000F7OJYX1.SGD","BK4581","BK4585","LU2089283258.USD","LU2347655073.USD","LU0203345920.USD","SG9999001440.SGD","IE00BVYPNV92.GBP","IE00BN8TJ469.HKD","LU0170899867.USD","LU1037948897.HKD","IE0002141913.USD","BK4566","LU0868494617.USD","LU1551013342.USD","LU2237443622.USD","LU1548497426.USD","IE00B3PB1722.GBP","LU0726765562.USD","LU2125909247.SGD","LU1839511570.USD","LU1003077747.HKD","LU0069063385.USD","LU1718418525.SGD","SG9999003800.SGD","LU1291159041.SGD","LU0942090050.USD","LU1732800096.USD","LU1244550221.USD","LU0882574055.USD","LU0203347892.USD","IE00B19Z3B42.SGD","LU1267930490.SGD","AGNG","LU0943347566.SGD","IE00BLSP4239.USD","IE00BDGV0183.EUR","LU0256863811.USD","LU2237443895.HKD","VHT","LU0289739343.SGD","LU0310799852.SGD","IE00BLSP4452.SGD","IE000WAW04H5.SGD","LU2237443382.USD","LU0122379950.USD","LU0820561909.HKD","LU0057025933.USD","LU0310800379.SGD","LU2433249047.HKD","LU0868494708.USD","LU2129689431.USD","LU1093756168.USD","LU0124676726.USD","LU0545039389.USD","IE00B19Z3581.USD","LU0320765646.SGD","LU1720051108.HKD","LU2089284900.SGD","LU1720051017.SGD","LU1929549753.HKD","LU2357305700.SGD","LU2237443549.SGD","LU1496350171.SGD","LU0234570918.USD","LU0432979614.USD","LU0098860793.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126099166","title":"艾伯维与Iambic达成合作：前期付款、里程碑付款及分级版税条款揭晓","url":"https://stock-news.laohu8.com/highlight/detail?id=1126099166","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126099166?lang=zh_cn&edition=full","pubTime":"2026-09-21 20:02","pubTimestamp":1789992127,"startTime":"0","endTime":"0","summary":"艾伯维公司与Iambic生物科技公司达成一项合作协议。根据协议，Iambic将获得一笔前期付款、若干里程碑付款，以及基于合作进展的分级版税收入。Iambic不仅将收到首笔预付款项，还有望在达成特定开发、监管及商业化里程碑时，陆续收获额外资金。同时，分级版税机制也为其长期收益提供了保障。艾伯维作为大型制药企业，显然看中了Iambic在相关领域的研发潜力；而对Iambic而言，这笔交易不仅输血助力，更是验证其技术平台价值的重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739343.SGD","LU0661504455.SGD","LU1548497426.USD","SG9999003800.SGD","VHT","LU2125909247.SGD","IE000F7OJYX1.SGD","LU1057294990.SGD","LU1670628061.USD","MEDX","IE00BSNM7G36.USD","LU0417517546.SGD","LU1989772923.USD","IE00BGHQF631.EUR","LU0861579265.USD","LU0942090050.USD","LU1267930573.SGD","LU1291159041.SGD","LU1023059063.AUD","LU2237443465.HKD","LU1989771016.USD","LU1074936037.SGD","LU0158827948.USD","LU2112291526.USD","LU1093756168.USD","SG9999001440.SGD","LU2357305700.SGD","PJP","LU2357627491.SGD","LU0124676726.USD","BK4566","LU1236620834.HKD","IE000WAW04H5.SGD","LU0069063385.USD","BK4533","JDOC","LU1585245621.USD","AGNG","LU0211328371.USD","LU0203345920.USD","LU2347655156.SGD","LU1934455863.HKD","IE00BFTCPJ56.SGD","LU0823416689.USD","LU0965508806.USD","LU1839511570.USD","LU0289739699.SGD","BK4559","LU1923622614.USD","LU1718418525.SGD","LU1037948541.HKD","LU1236620750.USD","LU1732800096.USD","LU0234570918.USD","LU2089283258.USD","IE0002141913.USD","LU0128525929.USD","IE00B2B36J28.USD","LU1037948897.HKD","LU2347655073.USD","LU1093756325.SGD","LU1267930490.SGD","IE00B3PB1722.GBP","LU0122379950.USD","LU2125909593.SGD","BK4550","LU0689626769.HKD","BK4534","LU0395794307.EUR","BK4588","LU0472753341.HKD","LU2237443382.USD","LU1929549753.HKD","IE00BLSP4452.SGD","LU1244550577.SGD","LU0965509010.AUD","LU0098860793.USD","IE00BJJMRZ35.SGD","LU2129689431.USD","LU0553294199.USD","LU0795875169.SGD","TRUH","IE0002270589.USD","LU1720051108.HKD","LU0985320562.USD","LU0708994859.HKD","LU2133065610.SGD","LU1244550494.USD","LU2237443549.SGD","LU0820561909.HKD","LU1551013342.USD","IE00B19Z3581.USD","LU0689472784.USD","LU2089984988.USD","LU2129689514.USD","LU1061106388.HKD","LU0868494708.USD","LU2237443978.SGD","GLAM","LU0511384066.AUD","FTXH","IE00BDGV0183.EUR","LU0820561818.USD","LU0256863811.USD","LU0170899867.USD","BK4581","LU0545039389.USD","FHLC","ABBV","IE00B19Z3B42.SGD","LU0198837287.USD","LU0726765562.USD","LU0058720904.USD","IXJ","IE00BVYPNV92.GBP","LU1003077747.HKD","XLV","LU1983299246.USD","IE000BZT7R73.USD","LU0289961442.SGD","LU0310799852.SGD","LU0456855351.SGD","SG9999011175.SGD","LU0949170772.SGD","LU0882574055.USD","LU1732799900.SGD","SG9999015986.USD","LU0057025933.USD","IE00BN8TJ469.HKD","LU2023251221.USD","RXL","LU0203347892.USD","LU0859254822.USD","PPH","IE00B4R5TH58.HKD","LU2468319806.SGD","IE0009355771.USD","LU1934455277.USD","IE00BJT1NW94.SGD","IE0000B7K699.USD","LU0943347566.SGD","LU1720051017.SGD","LU0114720955.EUR","LU0795875086.SGD","SG9999015952.SGD","IE00BLSP4239.USD","IE000SO60NU8.SGD","LU1670627923.USD","LU1430594728.SGD","LU0868494617.USD","LU1244550221.USD","LU1496350171.SGD","LU1989772840.SGD","IE000MB6IJN5.SGD","LU2087621335.USD","LU0320765646.SGD","LU1934455194.USD","LU0965509283.SGD","LU2129689605.HKD","LU2433249047.HKD","LU1551013425.SGD","LU1496350502.SGD","LU0310800379.SGD","LU2089284900.SGD","IE00BVYPNW00.USD","BK4139","IE00B42XCP33.USD","SG9999015945.SGD","LU1162221912.USD","LU0912757837.SGD","LU0256863902.USD","LU0965509101.SGD","IYH","SG9999015978.USD","IE0004445239.USD","LU2237443622.USD","IE00BBT3K403.USD","LU2237443895.HKD","LU0432979614.USD","LU0211327993.USD","LU0234572021.USD","LU0738911758.USD","BK4585","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145849702","title":"艾伯维高管：受医保报销时间影响，Tavapadon美国上市预计将呈“慢热”态势——电话会议实录","url":"https://stock-news.laohu8.com/highlight/detail?id=1145849702","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145849702?lang=zh_cn&edition=full","pubTime":"2026-09-15 22:32","pubTimestamp":1789482730,"startTime":"0","endTime":"0","summary":"在最近的一场电话会议中，艾伯维公司高层透露，其帕金森病新药Tavapadon在美国市场的上市进程，恐怕会迎来一场“慢热”开局。这背后的关键推手，正是医疗保险报销的时间节点问题。该高管指出，由于Medicare的报销政策在时间上存在特定安排，Tavapadon的商业化放量节奏或将受到明显牵制。这一预判，无疑为观察者们提供了一个审视美国药品市场准入复杂性的鲜活样本。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739343.SGD","LU0661504455.SGD","SG9999003800.SGD","VHT","LU2125909247.SGD","IE000F7OJYX1.SGD","LU1057294990.SGD","LU1670628061.USD","MEDX","IE00BSNM7G36.USD","LU0417517546.SGD","LU1989772923.USD","IE00BGHQF631.EUR","LU0861579265.USD","LU0942090050.USD","LU1267930573.SGD","LU1291159041.SGD","LU1023059063.AUD","LU2237443465.HKD","LU1989771016.USD","LU1074936037.SGD","LU0158827948.USD","LU2112291526.USD","LU1093756168.USD","SG9999001440.SGD","PJP","LU2357627491.SGD","LU0124676726.USD","BK4566","LU1236620834.HKD","IE000WAW04H5.SGD","LU0069063385.USD","BK4533","JDOC","LU1585245621.USD","AGNG","LU0211328371.USD","LU0203345920.USD","LU2347655156.SGD","LU1934455863.HKD","IE00BFTCPJ56.SGD","LU0823416689.USD","LU0965508806.USD","LU1839511570.USD","LU0289739699.SGD","BK4559","LU1923622614.USD","LU1718418525.SGD","LU1037948541.HKD","LU1236620750.USD","LU1732800096.USD","LU0234570918.USD","LU2089283258.USD","IE0002141913.USD","LU0128525929.USD","IE00B2B36J28.USD","LU1037948897.HKD","LU2347655073.USD","LU1093756325.SGD","LU1267930490.SGD","IE00B3PB1722.GBP","LU0122379950.USD","LU2125909593.SGD","BK4550","LU0689626769.HKD","BK4534","LU0395794307.EUR","BK4588","LU0472753341.HKD","LU2237443382.USD","LU1929549753.HKD","IE00BLSP4452.SGD","LU1244550577.SGD","LU0965509010.AUD","LU0098860793.USD","IE00BJJMRZ35.SGD","LU2129689431.USD","LU0553294199.USD","LU0795875169.SGD","TRUH","IE0002270589.USD","LU0985320562.USD","LU0708994859.HKD","LU2133065610.SGD","LU1244550494.USD","LU2237443549.SGD","LU0820561909.HKD","LU1551013342.USD","IE00B19Z3581.USD","LU0689472784.USD","LU2089984988.USD","LU2129689514.USD","LU1061106388.HKD","LU0868494708.USD","LU2237443978.SGD","GLAM","LU0511384066.AUD","FTXH","IE00BDGV0183.EUR","LU0820561818.USD","LU0256863811.USD","LU0170899867.USD","BK4581","LU0545039389.USD","FHLC","ABBV","IE00B19Z3B42.SGD","LU0198837287.USD","LU0726765562.USD","LU0058720904.USD","IXJ","IE00BVYPNV92.GBP","LU1003077747.HKD","XLV","LU1983299246.USD","IE000BZT7R73.USD","LU0289961442.SGD","LU0310799852.SGD","LU0456855351.SGD","SG9999011175.SGD","LU0949170772.SGD","LU0882574055.USD","LU1732799900.SGD","SG9999015986.USD","LU0057025933.USD","IE00BN8TJ469.HKD","LU2023251221.USD","RXL","LU0203347892.USD","LU0859254822.USD","PPH","IE00B4R5TH58.HKD","LU2468319806.SGD","IE0009355771.USD","LU1934455277.USD","IE00BJT1NW94.SGD","IE0000B7K699.USD","LU0943347566.SGD","LU0114720955.EUR","LU0795875086.SGD","SG9999015952.SGD","IE00BLSP4239.USD","IE000SO60NU8.SGD","LU1670627923.USD","LU1430594728.SGD","LU0868494617.USD","LU1244550221.USD","LU1496350171.SGD","LU1989772840.SGD","IE000MB6IJN5.SGD","LU2087621335.USD","LU0320765646.SGD","LU1934455194.USD","LU0965509283.SGD","LU2129689605.HKD","LU2433249047.HKD","LU1551013425.SGD","LU1496350502.SGD","LU0310800379.SGD","LU2089284900.SGD","IE00BVYPNW00.USD","BK4139","IE00B42XCP33.USD","SG9999015945.SGD","LU1162221912.USD","LU0912757837.SGD","LU0256863902.USD","LU0965509101.SGD","IYH","SG9999015978.USD","IE0004445239.USD","LU2237443622.USD","IE00BBT3K403.USD","LU2237443895.HKD","LU0432979614.USD","LU0211327993.USD","LU0234572021.USD","LU0738911758.USD","BK4585","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100769493","title":"艾伯维高管：血癌药物Etentamig晚期数据将于9月下旬在国际骨髓瘤学会会议上公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1100769493","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100769493?lang=zh_cn&edition=full","pubTime":"2026-09-15 22:28","pubTimestamp":1789482491,"startTime":"0","endTime":"0","summary":"在近期的一次电话会议中，艾伯维公司高层透露，其备受关注的血癌治疗药物Etentamig的晚期临床数据，已确定将在今年9月下旬的国际骨髓瘤学会会议上正式亮相。\n这一重磅消息，由公司高管在会议期间亲自确认并对外释放。据悉，该药物的关键性试验结果，选择在国际顶级专业学术平台首发，足见其数据的重要性和潜在的行业影响力。此次披露，无疑为血液肿瘤治疗领域投下了一枚深水炸弹，引发业界广泛关注与期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1496350502.SGD","LU0198837287.USD","IE00B19Z3B42.SGD","IE00BBT3K403.USD","LU0912757837.SGD","LU0965509010.AUD","LU2129689605.HKD","LU1732800096.USD","LU1551013342.USD","LU1934455277.USD","LU0661504455.SGD","IE0009355771.USD","LU0795875086.SGD","LU1236620750.USD","IE00BFTCPJ56.SGD","ABBV","LU1934455863.HKD","SG9999015978.USD","LU0820561818.USD","BK4559","LU0234570918.USD","IE000SO60NU8.SGD","LU2347655073.USD","LU1551013425.SGD","LU2089284900.SGD","LU0861579265.USD","LU0211328371.USD","LU1023059063.AUD","IE000F7OJYX1.SGD","LU1989771016.USD","IE000BZT7R73.USD","LU1244550221.USD","LU0456855351.SGD","LU0432979614.USD","TRUH","LU1037948897.HKD","BK4581","LU0708994859.HKD","LU2237443895.HKD","AGNG","SG9999003800.SGD","IE00B2B36J28.USD","LU0310799852.SGD","LU0057025933.USD","IE0004445239.USD","LU1267930490.SGD","LU0965509283.SGD","LU1983299246.USD","LU2357627491.SGD","LU0256863811.USD","IE0000B7K699.USD","FTXH","LU2087621335.USD","LU1929549753.HKD","LU0942090050.USD","IE00BJT1NW94.SGD","LU0965508806.USD","LU0098860793.USD","LU1585245621.USD","LU2237443549.SGD","LU0320765646.SGD","LU0985320562.USD","SG9999011175.SGD","LU2125909247.SGD","LU0029864427.USD","LU0726765562.USD","IE00BN8TJ469.HKD","IE0002270589.USD","BK4585","LU0124676726.USD","LU1162221912.USD","LU0859254822.USD","LU1093756325.SGD","BK4139","IXJ","LU1074936037.SGD","LU2089283258.USD","IE000WAW04H5.SGD","LU1989772840.SGD","LU0289739699.SGD","IE00BGHQF631.EUR","LU1244550577.SGD","IE00BJJMRZ35.SGD","PJP","BK4588","LU0211327993.USD","IE00BDGV0183.EUR","IE0002141913.USD","LU0170899867.USD","IE000MB6IJN5.SGD","LU1923622614.USD","IE00B4R5TH58.HKD","LU0256863902.USD","SG9999001440.SGD","LU1839511570.USD","LU2237443978.SGD","LU1037948541.HKD","PPH","LU0795875169.SGD","LU0310800379.SGD","LU1496350171.SGD","LU0689626769.HKD","LU0234572021.USD","RXL","SG9999015986.USD","LU2133065610.SGD","BK4550","GLAM","FHLC","LU1430594728.SGD","IE00BVYPNW00.USD","LU0395794307.EUR","LU0553294199.USD","LU0417517546.SGD","LU1244550494.USD","LU0820561909.HKD","LU2237443382.USD","LU0114720955.EUR","IE00BLSP4452.SGD","LU1670628061.USD","LU1267930573.SGD","JDOC","LU2347655156.SGD","LU0069063385.USD","BK4534","LU2433249047.HKD","LU2023251221.USD","LU0203345920.USD","VHT","LU2237443465.HKD","BK4566","IE00B3PB1722.GBP","LU2129689431.USD","IYH","LU1003077747.HKD","LU0965509101.SGD","SG9999015945.SGD","LU1718418525.SGD","LU0203347892.USD","LU2468319806.SGD","IE00BVYPNV92.GBP","LU0545039389.USD","LU0738911758.USD","LU1291159041.SGD","LU1989772923.USD","LU1057294990.SGD","LU2089984988.USD","LU1061106388.HKD","SG9999015952.SGD","IE00BSNM7G36.USD","LU0689472784.USD","LU2237443622.USD","LU0868494617.USD","LU0949170772.SGD","BK4533","LU2129689514.USD","LU0868494708.USD","LU2125909593.SGD","LU0472753341.HKD","LU0943347566.SGD","LU0882574055.USD","LU1934455194.USD","LU1236620834.HKD","LU0823416689.USD","LU0128525929.USD","LU1670627923.USD","LU2112291526.USD","LU0289961442.SGD","IE00B42XCP33.USD","IE00BLSP4239.USD","MEDX","LU0122379950.USD","XLV","LU0058720904.USD","LU0511384066.AUD","LU0158827948.USD","LU0289739343.SGD","LU1093756168.USD","LU1732799900.SGD","IE00B19Z3581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148213172","title":"艾伯维高管透露：今年将启动Apogee的Zumilokibart患者入组，目标2030年初上市——电话会议纪要","url":"https://stock-news.laohu8.com/highlight/detail?id=1148213172","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148213172?lang=zh_cn&edition=full","pubTime":"2026-09-15 22:23","pubTimestamp":1789482194,"startTime":"0","endTime":"0","summary":"在近日召开的一场电话会议中，艾伯维公司高管明确表态，公司计划于今年正式启动针对Apogee旗下药物Zumilokibart的患者入组工作。此举被视为该药物研发进程中的关键一步，标志着其临床试验阶段即将全面铺开。Zumilokibart作为Apogee的核心资产之一，其进展速度与质量，将直接影响公司未来数年的产品组合竞争力。展望未来，随着入组工作的逐步展开，更多关于Zumilokibart的疗效与安全性数据将陆续浮出水面。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2347655073.USD","LU0203345920.USD","LU0912757837.SGD","LU0417517546.SGD","LU2089283258.USD","IYH","LU1037948541.HKD","IE000F7OJYX1.SGD","IE00BBT3K403.USD","LU2112291526.USD","LU0124676726.USD","LU2125909593.SGD","LU2433249047.HKD","IXJ","SG9999003800.SGD","LU0098860793.USD","PJP","PPH","LU1236620834.HKD","IE0002270589.USD","LU1244550494.USD","LU0310799852.SGD","LU0942090050.USD","LU1267930573.SGD","LU1670628061.USD","LU0545039389.USD","LU2237443978.SGD","LU1585245621.USD","FTXH","LU0310800379.SGD","IE00BVYPNV92.GBP","IE000SO60NU8.SGD","SG9999015986.USD","LU0211327993.USD","LU2087621335.USD","LU0553294199.USD","LU2347655156.SGD","LU1023059063.AUD","LU0472753341.HKD","LU1162221912.USD","LU0122379950.USD","LU0661504455.SGD","LU2125909247.SGD","LU0868494708.USD","LU2023251221.USD","LU0114720955.EUR","LU1074936037.SGD","LU0029864427.USD","LU0868494617.USD","LU0726765562.USD","LU2357627491.SGD","VHT","LU0820561818.USD","BK4581","LU0320765646.SGD","FHLC","IE00BN8TJ469.HKD","IE00BSNM7G36.USD","LU1929549753.HKD","LU2129689605.HKD","IE00BVYPNW00.USD","LU2237443622.USD","LU1989772840.SGD","LU0170899867.USD","LU0198837287.USD","LU0985320562.USD","LU1934455277.USD","LU1839511570.USD","BK4559","LU0057025933.USD","LU2089284900.SGD","SG9999015952.SGD","LU0965508806.USD","BK4585","LU1989771016.USD","LU2089984988.USD","LU1934455194.USD","RXL","LU1732799900.SGD","LU2237443895.HKD","LU1430594728.SGD","LU1989772923.USD","GLAM","IE0002141913.USD","LU0203347892.USD","BK4534","LU1496350502.SGD","LU1267930490.SGD","IE000MB6IJN5.SGD","LU0859254822.USD","LU0965509101.SGD","LU2133065610.SGD","LU1551013342.USD","SG9999001440.SGD","LU0795875169.SGD","SG9999015978.USD","MEDX","LU1057294990.SGD","LU0965509010.AUD","LU0158827948.USD","LU1934455863.HKD","LU0795875086.SGD","BK4139","IE00B4R5TH58.HKD","LU0820561909.HKD","LU0256863902.USD","LU0882574055.USD","LU1093756325.SGD","IE00BLSP4452.SGD","LU1061106388.HKD","LU0395794307.EUR","LU1551013425.SGD","LU0289739343.SGD","LU2129689431.USD","IE000WAW04H5.SGD","ABBV","BK4533","IE0009355771.USD","LU2237443465.HKD","LU0943347566.SGD","LU0432979614.USD","LU1983299246.USD","LU2129689514.USD","XLV","LU2237443382.USD","LU1496350171.SGD","IE00B42XCP33.USD","LU1236620750.USD","LU0689626769.HKD","IE00B3PB1722.GBP","LU0456855351.SGD","LU1093756168.USD","LU0256863811.USD","SG9999011175.SGD","IE00BDGV0183.EUR","LU1003077747.HKD","IE0004445239.USD","BK4588","LU0861579265.USD","JDOC","LU0949170772.SGD","IE00B2B36J28.USD","IE00B19Z3581.USD","LU1923622614.USD","LU0289961442.SGD","LU1718418525.SGD","LU0069063385.USD","TRUH","LU0689472784.USD","LU0211328371.USD","LU0965509283.SGD","IE0000B7K699.USD","IE00BGHQF631.EUR","LU0128525929.USD","LU0823416689.USD","LU1732800096.USD","SG9999015945.SGD","IE00BJT1NW94.SGD","LU0708994859.HKD","LU1291159041.SGD","BK4566","IE00B19Z3B42.SGD","LU1037948897.HKD","LU2468319806.SGD","IE00BFTCPJ56.SGD","LU1244550221.USD","LU0511384066.AUD","LU1670627923.USD","BK4550","LU0289739699.SGD","LU0738911758.USD","LU0058720904.USD","AGNG","LU1244550577.SGD","IE00BJJMRZ35.SGD","LU0234570918.USD","LU2237443549.SGD","IE000BZT7R73.USD","IE00BLSP4239.USD","LU0234572021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176903671","title":"艾伯维高管：现有产品组合为未来十年强劲增长提供\"清晰视野\"——电话会议实录","url":"https://stock-news.laohu8.com/highlight/detail?id=1176903671","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176903671?lang=zh_cn&edition=full","pubTime":"2026-09-15 22:21","pubTimestamp":1789482069,"startTime":"0","endTime":"0","summary":"在最近的一次电话会议中，艾伯维公司高管明确表示，公司目前的产品组合已然构筑起一道通往未来十年超强增长的\"清晰路径\"。这一表态，无疑为市场注入了强劲的信心。据其所述，凭借现有的业务布局与管线储备，公司完全有能力在相当长的时期内维持令人瞩目的发展势头，这不仅是对当下实力的肯定，更是对未来潜力的有力背书。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","LU0310800379.SGD","LU2125909247.SGD","MEDX","LU0795875086.SGD","IXJ","LU1839511570.USD","SG9999011175.SGD","IE000WAW04H5.SGD","BK4559","LU1003077747.HKD","LU1023059063.AUD","LU2468319806.SGD","BK4534","FHLC","LU1093756325.SGD","IYH","PPH","LU1585245621.USD","LU2023251221.USD","LU1670628061.USD","LU0456855351.SGD","IE00BVYPNV92.GBP","LU0114720955.EUR","SG9999015945.SGD","LU1037948897.HKD","IE00BLSP4239.USD","LU0859254822.USD","SG9999015986.USD","BK4139","LU0738911758.USD","VHT","BK4585","IE000MB6IJN5.SGD","LU0912757837.SGD","LU0820561909.HKD","LU1244550577.SGD","LU2112291526.USD","LU0211327993.USD","LU2129689605.HKD","LU1989772840.SGD","LU0553294199.USD","LU0708994859.HKD","LU2237443978.SGD","LU1430594728.SGD","GLAM","LU0170899867.USD","IE0002270589.USD","RXL","LU2089283258.USD","BK4581","LU1989772923.USD","LU1267930490.SGD","LU1983299246.USD","LU0158827948.USD","LU2125909593.SGD","LU0868494617.USD","LU0949170772.SGD","LU1551013425.SGD","LU1718418525.SGD","IE00BDGV0183.EUR","LU0689472784.USD","LU0965509101.SGD","LU1267930573.SGD","IE00BJJMRZ35.SGD","JDOC","LU0098860793.USD","LU1291159041.SGD","LU2129689514.USD","LU0124676726.USD","LU0823416689.USD","IE0002141913.USD","SG9999003800.SGD","IE00BGHQF631.EUR","LU0320765646.SGD","LU2347655156.SGD","LU0545039389.USD","IE00BLSP4452.SGD","LU0395794307.EUR","LU0211328371.USD","LU0310799852.SGD","LU2133065610.SGD","LU1162221912.USD","IE00BSNM7G36.USD","LU2237443549.SGD","TRUH","IE00B19Z3581.USD","LU0472753341.HKD","IE00BN8TJ469.HKD","IE00BJT1NW94.SGD","LU0289739343.SGD","LU0942090050.USD","LU0965508806.USD","LU1496350502.SGD","LU1244550494.USD","LU0122379950.USD","LU0432979614.USD","IE00BBT3K403.USD","LU1551013342.USD","LU0029864427.USD","ABBV","LU0203347892.USD","LU0256863902.USD","LU0868494708.USD","LU0726765562.USD","SG9999015952.SGD","LU0795875169.SGD","LU0965509283.SGD","LU2357627491.SGD","LU0289961442.SGD","LU1074936037.SGD","BK4550","LU1236620750.USD","LU1093756168.USD","LU1236620834.HKD","LU1934455277.USD","LU0689626769.HKD","IE00B2B36J28.USD","LU1929549753.HKD","LU0985320562.USD","AGNG","LU2237443622.USD","LU2237443465.HKD","BK4566","LU0128525929.USD","IE0000B7K699.USD","LU0234570918.USD","IE00BFTCPJ56.SGD","LU2347655073.USD","LU0820561818.USD","LU1061106388.HKD","LU1496350171.SGD","LU1037948541.HKD","IE00B42XCP33.USD","LU0417517546.SGD","LU0203345920.USD","IE000BZT7R73.USD","BK4588","LU0256863811.USD","LU2089284900.SGD","SG9999015978.USD","LU0069063385.USD","IE0009355771.USD","LU2087621335.USD","LU1244550221.USD","IE0004445239.USD","PJP","LU2129689431.USD","LU0058720904.USD","IE000F7OJYX1.SGD","LU0289739699.SGD","IE00B3PB1722.GBP","XLV","LU0661504455.SGD","LU0965509010.AUD","LU0198837287.USD","LU2237443895.HKD","LU2237443382.USD","LU1732799900.SGD","IE00BVYPNW00.USD","LU1934455194.USD","LU1057294990.SGD","LU0861579265.USD","LU1934455863.HKD","SG9999001440.SGD","LU1670627923.USD","LU0234572021.USD","LU1732800096.USD","IE00B4R5TH58.HKD","LU1989771016.USD","LU0511384066.AUD","LU0943347566.SGD","LU0882574055.USD","LU2089984988.USD","LU2433249047.HKD","IE000SO60NU8.SGD","BK4533","LU1923622614.USD","FTXH","LU0057025933.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191303955","title":"艾伯维高管：稳健资产负债表与长期成长空间并存，公司可兼顾早期及晚期业务拓展机会——电话会议实录","url":"https://stock-news.laohu8.com/highlight/detail?id=1191303955","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191303955?lang=zh_cn&edition=full","pubTime":"2026-09-09 22:56","pubTimestamp":1788965760,"startTime":"0","endTime":"0","summary":"在近日一场备受关注的电话会议中，艾伯维公司高管明确表示，凭借其稳健的资产负债表以及充裕的长期增长跑道，公司目前能够同时审视并把握早期与晚期阶段的业务拓展契机。这一表态暗示，这家制药巨头在战略布局上拥有充分的灵活性与多元选择空间，既可着眼于处于萌芽阶段的创新资产，亦不排除对相对成熟项目的果断介入。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211328371.USD","LU0211327993.USD","LU0395794307.EUR","LU0965509283.SGD","LU0726765562.USD","LU0511384066.AUD","IE00BBT3K403.USD","LU0553294199.USD","IXJ","LU0432979614.USD","PJP","LU1037948897.HKD","LU2129689605.HKD","SG9999015945.SGD","LU0098860793.USD","LU0823416689.USD","LU0795875169.SGD","IE00BJJMRZ35.SGD","LU1496350502.SGD","IE0002141913.USD","LU1291159041.SGD","IE00BSNM7G36.USD","IE00BVYPNV92.GBP","LU0310799852.SGD","LU0158827948.USD","LU1162221912.USD","LU1244550577.SGD","LU2129689431.USD","LU1236620750.USD","AGNG","LU0289739699.SGD","BK4585","IE00BJT1NW94.SGD","LU1732800096.USD","LU1023059063.AUD","LU0942090050.USD","IE00BDGV0183.EUR","LU1496350171.SGD","LU0689626769.HKD","LU0203345920.USD","LU0943347566.SGD","LU0128525929.USD","LU0661504455.SGD","LU1934455194.USD","LU0289961442.SGD","LU0868494617.USD","IYH","LU0029864427.USD","LU0861579265.USD","LU1061106388.HKD","LU1934455277.USD","IE00B19Z3581.USD","IE000SO60NU8.SGD","LU1670628061.USD","LU0320765646.SGD","IE000WAW04H5.SGD","ABBV","JDOC","LU1267930490.SGD","IE000F7OJYX1.SGD","IE00B4R5TH58.HKD","LU0114720955.EUR","LU0689472784.USD","LU1244550221.USD","SG9999003800.SGD","LU2112291526.USD","VHT","BK4581","IE00B2B36J28.USD","LU0069063385.USD","LU0057025933.USD","LU2023251221.USD","LU1551013342.USD","IE0009355771.USD","LU2089284900.SGD","TRUH","LU1670627923.USD","LU2237443465.HKD","LU0234572021.USD","IE0000B7K699.USD","LU1267930573.SGD","BK4588","LU0456855351.SGD","SG9999015986.USD","LU0708994859.HKD","LU0198837287.USD","LU1430594728.SGD","LU1093756168.USD","LU0203347892.USD","LU1093756325.SGD","LU0545039389.USD","LU1934455863.HKD","LU0122379950.USD","LU2133065610.SGD","LU0256863902.USD","IE00BLSP4452.SGD","LU0882574055.USD","BK4566","LU1057294990.SGD","LU2237443978.SGD","IE00B3PB1722.GBP","LU2237443382.USD","LU1923622614.USD","LU2089283258.USD","LU1037948541.HKD","SG9999001440.SGD","IE00BGHQF631.EUR","LU0738911758.USD","LU1732799900.SGD","LU0472753341.HKD","LU0912757837.SGD","FTXH","LU0820561909.HKD","LU0965509101.SGD","LU2468319806.SGD","SG9999011175.SGD","LU0820561818.USD","LU1585245621.USD","FHLC","LU0124676726.USD","LU0417517546.SGD","LU0058720904.USD","BK4139","SG9999015978.USD","IE000BZT7R73.USD","LU2433249047.HKD","BK4534","IE00BLSP4239.USD","LU2347655073.USD","LU2089984988.USD","IE00BVYPNW00.USD","LU2237443549.SGD","LU0289739343.SGD","LU2129689514.USD","IE0004445239.USD","PPH","LU0965509010.AUD","RXL","LU0234570918.USD","LU1074936037.SGD","IE000MB6IJN5.SGD","LU2237443622.USD","LU0868494708.USD","LU1929549753.HKD","LU1989772923.USD","LU2237443895.HKD","LU1236620834.HKD","LU1989771016.USD","LU1551013425.SGD","LU1244550494.USD","LU2125909593.SGD","LU0256863811.USD","IE00B19Z3B42.SGD","IE00BFTCPJ56.SGD","LU0859254822.USD","LU0949170772.SGD","LU2357627491.SGD","LU2125909247.SGD","BK4533","XLV","LU0310800379.SGD","GLAM","BK4550","MEDX","LU1839511570.USD","IE00B42XCP33.USD","LU1718418525.SGD","SG9999015952.SGD","LU0985320562.USD","LU0965508806.USD","LU1983299246.USD","IE00BN8TJ469.HKD","LU0170899867.USD","LU2087621335.USD","LU1989772840.SGD","LU2347655156.SGD","IE0002270589.USD","LU1003077747.HKD","LU0795875086.SGD","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199532337","title":"异动解读｜艾伯维公司盘中下跌3.13%，报248.42美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1199532337","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199532337?lang=zh_cn&edition=full","pubTime":"2026-09-09 03:51","pubTimestamp":1788897081,"startTime":"0","endTime":"0","summary":"9月9日，艾伯维公司盘中下跌3.13%，报248.42美元/股，成交额7.15亿美元。艾伯维公司所在的生物科技行业中，个股普遍承压，其中安进跌10.47%，Moderna跌3.59%，Ionis Pharmaceuticals跌3.22%，阿尔尼拉姆制药公司跌1.97%，Roivant Sciences逆势涨18.68%。艾伯维公司是一家全球性的、以研究为基础的生物制药公司，产品主要集中在慢性自身免疫性疾病、肿瘤、神经科学及医美等领域，核心产品包括Skyrizi、Rinvoq、Vraylar及BOTOX等。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABBV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664388058","title":"109亿美元重磅收购Apogee(APGE.US)落地！艾伯维(ABBV.US)完成2019年以来最大并购，预计2032年起贡献收益","url":"https://stock-news.laohu8.com/highlight/detail?id=2664388058","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664388058?lang=zh_cn&edition=full","pubTime":"2026-09-04 09:35","pubTimestamp":1788485746,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["SG9999003800.SGD","PPH","VHT","LU0234570918.USD","IE0002141913.USD","LU0128525929.USD","KCE","GLAM","FTXH","LU1267930490.SGD","MEDX","MYLD","LU0114720955.EUR","LU2125909593.SGD","XMMO","LU0170899867.USD","CALF","LU2087621335.USD","LU0320765646.SGD","FHLC","ABBV","IE00B19Z3B42.SGD","LU2129689605.HKD","LU2433249047.HKD","LU1551013425.SGD","LU2129689514.USD","PJP","IXJ","LU1496350502.SGD","LU0124676726.USD","LU0310800379.SGD","XLV","LU1236620834.HKD","IE000WAW04H5.SGD","LU0069063385.USD","TRUH","BK4533","JDOC","IYH","AGNG","LU0203345920.USD","LU2237443895.HKD","APGE","LU2237443549.SGD","LU1839511570.USD","LU0820561909.HKD","SBIO","RXL","LU2089984988.USD","LU0859254822.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664053388","title":"109亿美元重磅收购Apogee(APGE.US)落地！艾伯维(ABBV.US)完成2019年以来最大并购，预计2032年起贡献收益","url":"https://stock-news.laohu8.com/highlight/detail?id=2664053388","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664053388?lang=zh_cn&edition=full","pubTime":"2026-09-04 09:35","pubTimestamp":1788485746,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，艾伯维于周四表示，公司已完成对抗炎药物研发商 Apogee Therapeutics价值 109 亿美元的收购。笔交易是这家制药巨头自 2019 年以来规模最大的补强型收购，智通财经AAPP于今年 6 月首次对此进行了报道。艾伯维预计，该项收购将对其调整后稀释每股收益产生负面影响，其中 2026 年将减少 0.14 美元，2027 年减少约 0.46 美元，并预计将于 2032 年开始实现增益。该指引已包含与完成 Apogee 收购相关的每股 0.14 美元稀释效应。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491888.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0256863902.USD","APGE","IE00B2B36J28.USD","KCE","LU0124676726.USD","LU1037948541.HKD","IE00B19Z3581.USD","BK4559","MYLD","SG9999011175.SGD","AGNG","IE00B4R5TH58.HKD","LU0203345920.USD","LU0985320562.USD","CALF","MEDX","SBIO","IE0004445239.USD","IXJ","ABBV","GLAM","IE00BN8TJ469.HKD","JDOC","LU2237443549.SGD","BK4566","PPH","IE0002270589.USD","XLV","TRUH","PJP","BK4581","LU1934455194.USD","LU0289739343.SGD","LU2089283258.USD","IYH","LU0170899867.USD","RXL","XMMO","FHLC","LU0057025933.USD","LU1983299246.USD","IE00BLSP4239.USD","LU1003077747.HKD","LU1236620834.HKD","VHT","FTXH","LU1989772840.SGD","LU1093756168.USD","LU0965509283.SGD","LU1718418525.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112455320","title":"艾伯维公布Cervino三期试验积极顶线结果：Etentamig显著提升复发/难治性多发性骨髓瘤患者缓解率与无进展生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=1112455320","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112455320?lang=zh_cn&edition=full","pubTime":"2026-09-03 21:19","pubTimestamp":1788441558,"startTime":"0","endTime":"0","summary":"艾伯维公司今日宣布，其针对复发或难治性多发性骨髓瘤患者的关键性Cervino三期临床试验，取得了积极的顶线数据。研究结果显示，在研药物Etentamig不仅显著提高了患者的客观缓解率，更在延长无进展生存期方面展现出压倒性的统计学优势。Cervino试验是一项全球性的、随机、开放标签的注册研究，旨在评估Etentamig相较于标准治疗的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE000WAW04H5.SGD","LU0472753341.HKD","LU0395794307.EUR","IXJ","LU0553294199.USD","SG9999003800.SGD","LU1162221912.USD","LU1037948897.HKD","LU0820561909.HKD","LU0211328371.USD","SG9999015945.SGD","LU1718418525.SGD","LU1244550577.SGD","IE00BLSP4452.SGD","LU1003077747.HKD","VHT","IE00B19Z3581.USD","LU1983299246.USD","LU0310799852.SGD","LU0868494708.USD","IE00BLSP4239.USD","IE0009355771.USD","LU1923622614.USD","LU2125909593.SGD","BK4139","IE00BVYPNV92.GBP","IYH","LU2089284900.SGD","LU2237443978.SGD","LU0795875169.SGD","LU1934455277.USD","LU0256863902.USD","LU2347655073.USD","LU1074936037.SGD","LU2087621335.USD","LU0882574055.USD","LU0289739343.SGD","GLAM","LU0158827948.USD","LU0289961442.SGD","LU1929549753.HKD","LU1244550494.USD","LU1989772840.SGD","IE000BZT7R73.USD","TRUH","LU0114720955.EUR","LU0320765646.SGD","LU1551013342.USD","BK4566","LU2357627491.SGD","IE0004445239.USD","IE00BFTCPJ56.SGD","LU0859254822.USD","LU1093756325.SGD","LU1732799900.SGD","LU0943347566.SGD","LU0861579265.USD","LU1989771016.USD","SG9999015986.USD","XLV","LU0058720904.USD","LU0823416689.USD","LU0661504455.SGD","BK4588","BK4559","LU1061106388.HKD","LU2023251221.USD","LU0965508806.USD","IE00B4R5TH58.HKD","LU0122379950.USD","LU1267930573.SGD","LU2237443549.SGD","IE00BGHQF631.EUR","LU1989772923.USD","IE00BDGV0183.EUR","LU0511384066.AUD","IE000MB6IJN5.SGD","LU1839511570.USD","LU0689472784.USD","LU1496350171.SGD","LU0256863811.USD","LU0124676726.USD","LU0545039389.USD","IE00BJT1NW94.SGD","IE00B42XCP33.USD","LU2237443622.USD","LU0965509101.SGD","LU0128525929.USD","LU0965509010.AUD","LU0738911758.USD","PPH","JDOC","LU1236620834.HKD","SG9999011175.SGD","LU1236620750.USD","LU1670627923.USD","LU2089283258.USD","LU0211327993.USD","LU2237443382.USD","SG9999001440.SGD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","SG9999015952.SGD","LU1093756168.USD","LU1732800096.USD","LU0868494617.USD","LU0198837287.USD","LU1551013425.SGD","IE0002270589.USD","LU1037948541.HKD","LU0432979614.USD","LU2112291526.USD","BK4550","LU0057025933.USD","LU0795875086.SGD","BK4534","LU2129689605.HKD","MEDX","RXL","LU1585245621.USD","IE00B3PB1722.GBP","BK4581","LU0289739699.SGD","FHLC","LU0069063385.USD","LU0203347892.USD","IE000F7OJYX1.SGD","LU0689626769.HKD","LU2237443895.HKD","LU1934455863.HKD","LU2468319806.SGD","LU0029864427.USD","PJP","LU2433249047.HKD","LU0170899867.USD","FTXH","LU0726765562.USD","LU0965509283.SGD","SG9999015978.USD","LU0203345920.USD","LU2133065610.SGD","LU0985320562.USD","LU1244550221.USD","ABBV","LU1670628061.USD","IE00BSNM7G36.USD","LU2347655156.SGD","LU2089984988.USD","LU0234570918.USD","LU1430594728.SGD","LU0942090050.USD","LU2129689431.USD","BK4585","LU1267930490.SGD","LU0949170772.SGD","LU0708994859.HKD","LU0820561818.USD","IE0002141913.USD","IE0000B7K699.USD","BK4533","IE000SO60NU8.SGD","LU0456855351.SGD","LU1057294990.SGD","LU2129689514.USD","LU1934455194.USD","LU2125909247.SGD","IE00BN8TJ469.HKD","LU0417517546.SGD","IE00BVYPNW00.USD","AGNG","LU1291159041.SGD","LU1496350502.SGD","LU0912757837.SGD","IE00BBT3K403.USD","LU0234572021.USD","LU2237443465.HKD","LU0098860793.USD","IE00B19Z3B42.SGD","LU1023059063.AUD","LU0310800379.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169611288","title":"FDA：不会启动撤销仿制药批准的流程——这些仿制药参照的是Namenda产品","url":"https://stock-news.laohu8.com/highlight/detail?id=1169611288","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169611288?lang=zh_cn&edition=full","pubTime":"2026-08-31 20:55","pubTimestamp":1788180909,"startTime":"0","endTime":"0","summary":"根据《联邦公报》发布的信息，美国食品药品监督管理局（FDA）宣布，将不会启动撤销相关简化新药申请（ANDA）批准的程序。这些申请所参照的，正是涉及Namenda系列产品的上市申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234570918.USD","LU1057294990.SGD","LU0868494708.USD","LU0256863811.USD","LU0949170772.SGD","BK4533","LU0170899867.USD","GLAM","PPH","RXL","LU2468319806.SGD","SG9999015945.SGD","LU0472753341.HKD","IE000BZT7R73.USD","IE00BVYPNW00.USD","LU0124676726.USD","IE00B19Z3581.USD","LU0320765646.SGD","IE00B3PB1722.GBP","SG9999015986.USD","TRUH","MEDX","IE000F7OJYX1.SGD","LU1236620750.USD","LU0661504455.SGD","LU0417517546.SGD","SG9999011175.SGD","LU0203347892.USD","LU2129689605.HKD","IE00BJT1NW94.SGD","LU0432979614.USD","LU0882574055.USD","LU1929549753.HKD","LU1934455194.USD","LU0057025933.USD","LU2125909593.SGD","LU1670628061.USD","BK4585","IE0009355771.USD","IE00BLSP4452.SGD","LU1430594728.SGD","LU0820561909.HKD","LU2125909247.SGD","IE00BN8TJ469.HKD","LU1989771016.USD","BK4550","LU1023059063.AUD","BK4566","IE00B19Z3B42.SGD","FTXH","LU0912757837.SGD","LU1061106388.HKD","LU2433249047.HKD","LU2133065610.SGD","LU0069063385.USD","LU1074936037.SGD","LU1244550221.USD","LU0965508806.USD","LU1585245621.USD","LU0310799852.SGD","IE0000B7K699.USD","LU0965509010.AUD","LU1236620834.HKD","LU0029864427.USD","LU0234572021.USD","LU0203345920.USD","LU0058720904.USD","LU0689626769.HKD","LU1732799900.SGD","LU0553294199.USD","IE00BGHQF631.EUR","LU0820561818.USD","LU0211328371.USD","BK4534","LU0395794307.EUR","LU1244550494.USD","LU2237443549.SGD","LU1496350171.SGD","LU1732800096.USD","LU2112291526.USD","LU2347655073.USD","IE0002270589.USD","LU2023251221.USD","LU0289739699.SGD","LU1496350502.SGD","LU1162221912.USD","IXJ","VHT","LU0823416689.USD","LU1093756168.USD","IE0004445239.USD","IE00BVYPNV92.GBP","LU2089283258.USD","LU0795875169.SGD","LU2357627491.SGD","LU0211327993.USD","LU0965509101.SGD","SG9999015978.USD","LU0198837287.USD","LU0795875086.SGD","IE00B42XCP33.USD","IE00BJJMRZ35.SGD","IE00BLSP4239.USD","LU0708994859.HKD","LU1934455277.USD","LU1989772923.USD","LU2087621335.USD","LU0511384066.AUD","LU1718418525.SGD","LU0456855351.SGD","LU0128525929.USD","AGNG","LU1003077747.HKD","LU0158827948.USD","LU0985320562.USD","LU0861579265.USD","IYH","BK4588","LU2237443978.SGD","LU2129689514.USD","LU1923622614.USD","LU1037948541.HKD","LU0943347566.SGD","LU1934455863.HKD","SG9999001440.SGD","PJP","XLV","LU0256863902.USD","LU0289961442.SGD","IE00BDGV0183.EUR","LU0689472784.USD","LU1244550577.SGD","LU0868494617.USD","SG9999015952.SGD","LU2237443382.USD","LU2347655156.SGD","LU1291159041.SGD","LU0942090050.USD","LU0310800379.SGD","IE00BBT3K403.USD","LU1267930490.SGD","LU1551013342.USD","LU1839511570.USD","IE00B4R5TH58.HKD","LU1989772840.SGD","LU1093756325.SGD","SG9999003800.SGD","LU2089284900.SGD","LU2237443895.HKD","IE000SO60NU8.SGD","IE00B2B36J28.USD","LU0738911758.USD","LU0965509283.SGD","LU2089984988.USD","LU0098860793.USD","IE00BFTCPJ56.SGD","LU1551013425.SGD","LU2237443465.HKD","ABBV","LU1983299246.USD","IE00BSNM7G36.USD","BK4139","IE0002141913.USD","BK4559","LU1670627923.USD","LU0726765562.USD","BK4581","LU1037948897.HKD","FHLC","LU2237443622.USD","LU2129689431.USD","JDOC","LU0859254822.USD","LU0289739343.SGD","IE000WAW04H5.SGD","LU0545039389.USD","IE000MB6IJN5.SGD","LU0114720955.EUR","LU0122379950.USD","LU1267930573.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662639772","title":"伯维（ABBV）向EMA递交Skyrizi克罗恩病治疗上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2662639772","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662639772?lang=zh_cn&edition=full","pubTime":"2026-08-27 16:56","pubTimestamp":1787821007,"startTime":"0","endTime":"0","summary":"Skyrizi此前已经在银屑病、银屑病关节炎等多个自身免疫疾病领域拿到欧洲地区的获批资质，如若本次克罗恩病适应症顺利获批，将进一步拓宽该产品在欧洲炎症性肠病赛道的市场空间。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/ZDBhOTg3YTMxNzM2MjM3OTI3ODI2.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZDBhOTg3YTMxNzM2MjM3OTI3ODI2.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305377","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0128525929.USD","IE000F7OJYX1.SGD","EMA","LU1839511570.USD","TRUH","IPOS","LU1236620750.USD","AGNG","LU0198837287.USD","LU2089283258.USD","LU0472753341.HKD","RXL","LU2133065610.SGD","LU0965508806.USD","VHT","SG9999001440.SGD","FTXH","IYH","LU0289739699.SGD","LU1732799900.SGD","LU0234572021.USD","IXJ","LU1585245621.USD","LU2087621335.USD","IE0004445239.USD","MEDX","LU0058720904.USD","LU2237443622.USD","LU2023251221.USD","BK4533","PJP","PPH","LU1236620834.HKD","LU0661504455.SGD","LU0985320562.USD","BK4559","LU2125909247.SGD","LU2125909593.SGD","SG9999011175.SGD","FHLC","GLAM","LU0417517546.SGD","LU0882574055.USD","LU1989771016.USD","ABBV","XLV","JDOC","LU0114720955.EUR","IE00BLSP4239.USD","LU1267930573.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195775229","title":"艾伯维向欧洲药品管理局提交Skyrizi®（瑞莎珠单抗）皮下诱导治疗申请，针对中重度活动性克罗恩病成人患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1195775229","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195775229?lang=zh_cn&edition=full","pubTime":"2026-08-27 14:00","pubTimestamp":1787810433,"startTime":"0","endTime":"0","summary":"艾伯维公司已正式向欧洲药品管理局递交了一项监管申请，旨在寻求Skyrizi皮下注射剂型的上市许可。该申请针对的适应症为——用于治疗患有中重度活动性克罗恩病的成年患者，且此方案将作为诱导治疗手段。若此次申请获得批准，Skyrizi的皮下给药方式将为患者提供更为便捷的治疗选择，有望改善治疗依从性与患者体验。此次针对克罗恩病皮下诱导治疗的申请，进一步丰富了Skyrizi的潜在临床应用范围。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739343.SGD","LU0661504455.SGD","SG9999003800.SGD","VHT","LU2125909247.SGD","IE000F7OJYX1.SGD","LU1057294990.SGD","LU1670628061.USD","MEDX","IE00BSNM7G36.USD","LU0417517546.SGD","LU1989772923.USD","IE00BGHQF631.EUR","LU0861579265.USD","LU0942090050.USD","LU1267930573.SGD","LU1291159041.SGD","LU1023059063.AUD","LU2237443465.HKD","LU1989771016.USD","LU1074936037.SGD","LU0158827948.USD","LU2112291526.USD","LU1093756168.USD","SG9999001440.SGD","PJP","LU2357627491.SGD","LU0124676726.USD","BK4566","LU1236620834.HKD","IE000WAW04H5.SGD","LU0069063385.USD","BK4533","JDOC","LU1585245621.USD","AGNG","LU0211328371.USD","LU0203345920.USD","LU2347655156.SGD","LU1934455863.HKD","IE00BFTCPJ56.SGD","LU0823416689.USD","LU0965508806.USD","LU1839511570.USD","LU0289739699.SGD","BK4559","LU1923622614.USD","LU1718418525.SGD","LU1037948541.HKD","LU1236620750.USD","LU1732800096.USD","LU0234570918.USD","LU2089283258.USD","IE0002141913.USD","LU0128525929.USD","IE00B2B36J28.USD","LU1037948897.HKD","LU2347655073.USD","LU1093756325.SGD","LU1267930490.SGD","IE00B3PB1722.GBP","LU0122379950.USD","LU2125909593.SGD","BK4550","LU0689626769.HKD","BK4534","LU0395794307.EUR","BK4588","LU0472753341.HKD","LU2237443382.USD","LU1929549753.HKD","IE00BLSP4452.SGD","LU1244550577.SGD","LU0965509010.AUD","LU0098860793.USD","IE00BJJMRZ35.SGD","LU2129689431.USD","LU0553294199.USD","LU0795875169.SGD","TRUH","IE0002270589.USD","LU0985320562.USD","LU0708994859.HKD","LU2133065610.SGD","LU1244550494.USD","LU2237443549.SGD","LU0820561909.HKD","LU1551013342.USD","IE00B19Z3581.USD","LU0689472784.USD","LU2089984988.USD","LU2129689514.USD","LU1061106388.HKD","LU0868494708.USD","LU2237443978.SGD","GLAM","LU0511384066.AUD","FTXH","IE00BDGV0183.EUR","LU0820561818.USD","LU0256863811.USD","LU0170899867.USD","BK4581","LU0545039389.USD","FHLC","ABBV","IE00B19Z3B42.SGD","LU0198837287.USD","LU0726765562.USD","LU0058720904.USD","IXJ","IE00BVYPNV92.GBP","LU1003077747.HKD","XLV","LU1983299246.USD","IE000BZT7R73.USD","LU0289961442.SGD","LU0310799852.SGD","LU0456855351.SGD","SG9999011175.SGD","LU0949170772.SGD","LU0882574055.USD","LU1732799900.SGD","SG9999015986.USD","LU0057025933.USD","IE00BN8TJ469.HKD","LU2023251221.USD","RXL","LU0203347892.USD","LU0859254822.USD","PPH","IE00B4R5TH58.HKD","LU2468319806.SGD","IE0009355771.USD","LU1934455277.USD","IE00BJT1NW94.SGD","IE0000B7K699.USD","LU0943347566.SGD","LU0114720955.EUR","LU0795875086.SGD","SG9999015952.SGD","IE00BLSP4239.USD","IE000SO60NU8.SGD","LU1670627923.USD","LU1430594728.SGD","LU0868494617.USD","LU1244550221.USD","LU1496350171.SGD","LU1989772840.SGD","IE000MB6IJN5.SGD","LU2087621335.USD","LU0320765646.SGD","LU1934455194.USD","LU0965509283.SGD","LU2129689605.HKD","LU2433249047.HKD","LU1551013425.SGD","LU1496350502.SGD","LU0310800379.SGD","LU2089284900.SGD","IE00BVYPNW00.USD","BK4139","IE00B42XCP33.USD","SG9999015945.SGD","LU1162221912.USD","LU0912757837.SGD","LU0256863902.USD","LU0965509101.SGD","IYH","SG9999015978.USD","IE0004445239.USD","LU2237443622.USD","IE00BBT3K403.USD","LU2237443895.HKD","LU0432979614.USD","LU0211327993.USD","LU0234572021.USD","LU0738911758.USD","BK4585","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193640360","title":"异动解读｜艾伯维公司盘中上涨3.04%，多家投行密集上调目标价叠加管线催化延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1193640360","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193640360?lang=zh_cn&edition=full","pubTime":"2026-08-20 03:36","pubTimestamp":1787168214,"startTime":"0","endTime":"0","summary":"8月19日，艾伯维公司盘中上涨3.04%，报266.765美元/股，成交额8.13亿美元。消息面上，近期多家华尔街投行密集上调艾伯维目标价：Wolfe将评级上调至\"跑赢大盘\"并给予300美元目标价，富国银行上调目标价至300美元维持增持，巴克莱上调至300美元，摩根大通上调至285美元，美银上调至276美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABBV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156251729","title":"异动解读｜艾伯维公司盘中上涨3.03%，多家投行上调目标价叠加管线催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1156251729","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156251729?lang=zh_cn&edition=full","pubTime":"2026-08-19 00:19","pubTimestamp":1787069954,"startTime":"0","endTime":"0","summary":"8月19日，艾伯维公司盘中上涨3.03%，报257.915美元/股，成交额4.05亿美元。消息面上，近期多家华尔街投行密集上调艾伯维目标价。管线方面，艾伯维近日在ClinicalTrials平台登记了从荣昌生物引进的PD-1/VEGF双抗RC148全球III期临床试验，头对头对照帕博利珠单抗联合化疗用于一线非小细胞肺癌，标志着该资产进入后期开发阶段，进一步丰富公司肿瘤管线布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABBV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656597285","title":"艾伯维（ABBV）保妥适新适应症获FDA受理 有望成美国首款咬肌突出医美肉毒制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2656597285","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656597285?lang=zh_cn&edition=full","pubTime":"2026-08-04 21:03","pubTimestamp":1785848630,"startTime":"0","endTime":"0","summary":"艾伯维表示，本次申报是对成熟产品潜力的进一步挖掘，以此匹配不断变化的求美者需求。作为医美赛道重磅单品，新适应症如若获批，有望进一步巩固艾尔建美学在注射医美领域的市场地位。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/NmRmY2E4Njg2ODIwNjk0NjU5Mw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NmRmY2E4Njg2ODIwNjk0NjU5Mw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303400","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE000MB6IJN5.SGD","SG9999015952.SGD","SG9999015945.SGD","LU2089283258.USD","LU2433249047.HKD","LU0965509010.AUD","LU2129689605.HKD","LU0868494708.USD","GLAM","LU0708994859.HKD","VHT","IE000BZT7R73.USD","LU1670627923.USD","ABBV","IYH","LU0553294199.USD","LU1989771016.USD","LU0820561818.USD","LU1496350502.SGD","LU1989772923.USD","LU1430594728.SGD","RXL","LU0738911758.USD","TRUH","IE000SO60NU8.SGD","JDOC","LU0158827948.USD","MEDX","LU1989772840.SGD","IE00B2B36J28.USD","LU0912757837.SGD","LU2129689431.USD","XLV","LABU","IE00B3PB1722.GBP","LU0965509101.SGD","LU0795875169.SGD","BK4588","LU0289739699.SGD","AGNG","LU0098860793.USD","PPH","LU0942090050.USD","PJP","LU0320765646.SGD","IXJ","FTXH","FHLC","LU1670628061.USD","LU2125909593.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abbvie.com","stockEarnings":[{"period":"1week","weight":0.0014},{"period":"1month","weight":0.0055},{"period":"3month","weight":0.0434},{"period":"6month","weight":0.2624},{"period":"1year","weight":0.2096},{"period":"ytd","weight":0.1569}],"compareEarnings":[{"period":"1week","weight":0.0127},{"period":"1month","weight":0.0069},{"period":"3month","weight":0.0581},{"period":"6month","weight":0.2165},{"period":"1year","weight":0.1722},{"period":"ytd","weight":0.1311}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"艾伯维公司注册成立于2012年4月10日，是一家全球性的、以研究为基础的生物制药公司。Abbvie公司从事开发和销售先进的疗法，来解决一些世界上最复杂和严重的疾病。Abbvie公司的产品主要集中在慢性自身免疫性疾病领域，包括类风湿性关节炎，牛皮癣和克罗恩病，银屑病和克罗恩病;低睾酮，HIV，子宫内膜异位症;甲状腺疾病;帕金森病;和并发症的慢性肾脏疾病和囊性纤维化相关的或其他健康问题。","yearOnYearQuotes":[{"month":1,"riseRate":0.357143,"avgChangeRate":-0.019222},{"month":2,"riseRate":0.857143,"avgChangeRate":0.039081},{"month":3,"riseRate":0.714286,"avgChangeRate":0.001102},{"month":4,"riseRate":0.571429,"avgChangeRate":0.006536},{"month":5,"riseRate":0.642857,"avgChangeRate":0.004172},{"month":6,"riseRate":0.5,"avgChangeRate":0.019288},{"month":7,"riseRate":0.5,"avgChangeRate":0.011241},{"month":8,"riseRate":0.571429,"avgChangeRate":0.008439},{"month":9,"riseRate":0.571429,"avgChangeRate":0.01608},{"month":10,"riseRate":0.615385,"avgChangeRate":0.007438},{"month":11,"riseRate":0.769231,"avgChangeRate":0.063841},{"month":12,"riseRate":0.692308,"avgChangeRate":0.025718}],"exchange":"NYSE","name":"艾伯维公司","nameEN":"AbbVie"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾伯维公司(ABBV)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾伯维公司(ABBV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾伯维公司,ABBV,艾伯维公司股票,艾伯维公司股票老虎,艾伯维公司股票老虎国际,艾伯维公司行情,艾伯维公司股票行情,艾伯维公司股价,艾伯维公司股市,艾伯维公司股票价格,艾伯维公司股票交易,艾伯维公司股票购买,艾伯维公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾伯维公司(ABBV)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾伯维公司(ABBV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}